A Pilot Study to Evaluate the Immunogenic Effects of Window-of-Opportunity Fractionated Stereotactic Radiotherapy Combined With Atezolizumab for Patients With Newly Diagnosed WHO CNS Grade 4 Glioma (Glioblastoma Multiforme)

What this Trial Is About

Researchers are studying patients with newly diagnosed Glioblastoma Multiforme, a malignant brain tumor with a poor outlook. This early phase 1 pilot study aims to evaluate the immune effects of combining fractionated stereotactic radiotherapy (FSRT) with Atezolizumab (Tecentriq), an FDA-approved PD-L1 inhibitor drug. The study is led by Stony Brook University and focuses on how this combination may affect tumor progression and treatment safety. Participants will receive FSRT for 2 weeks along with two doses of Atezolizumab 840 mg intravenous (IV), one at the start and one at the end of the radiotherapy period. After this initial treatment, patients will have surgery to remove as much of the tumor as safely possible, following standard care. Post-surgery, patients will continue with normal glioblastoma care and receive Atezolizumab 840 mg IV every 2 weeks during the adjuvant treatment phase. During the study, participants will be closely monitored for tumor progression or relapse over 2 years after surgery and for treatment-related side effects within 30 days after the last Atezolizumab dose using standard criteria. Assessments will include clinical evaluations and safety monitoring. The total duration of involvement covers initial treatment, surgery, adjuvant therapy, and follow-up to assess outcomes and adverse events.

Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme